A retrospective analysis was performed in 173 consecutive patients with Graves' disease (GD) with the principal aim of evaluating the influences of subtotal (N = 157) and total (N = 19) thyroidectomy on postoperative recurrence rates, endocrine ophthalmopathy (EO) and thyrotropin receptor antibody (TSH-R-ab) titres. Postoperatively recurrent disease, identified by increased thyroid hormone levels, occurred in 32 patients (20%) who underwent subtotal resection. These recurrences were associated with over-representation of preoperative EO (p < 0.001) as well as high TSH-R-ab levels post \ x=req-\ operatively (p < 0.05\p=n-\0.01).Subtotal and total resections were followed by an aggravation of preoperative EO in nine (16%) and one (6%), and by a development of EO in two and none of the patients, respectively. Persistently elevated TSH-R-ab titers during thyrostatic therapy became close to normalized in seven (32%) and 15 (88%) of the patients undergoing subtotal or total thyroidectomies, respectively, which illustrates a thyroid tissue dependency of the autoantibody production. Among the total material of 173 patients, altogether 75 cases exhibited persistent or progressive EO and/or TSH\x=req-\ R-ab elevation after more than 1 year of preoperative thyrostatic treatment. In this group, recurrent GD or aggravated EO occurred in 23 (39%) of those operated with subtotal resection and in one (6%) of those undergoing total thyroidectomy (p < 0.05). The results thus indicate that EO, particularly at the time of surgery, and prevailing TSH-R-ab titers are associated with an increased risk of recurrent GD and suggest that patients exhibiting these characteristics should benefit from total rather than subtotal thyroidectomy.
The surgical treatment of Graves' disease (GD) char¬ acteristically comprises bilateral thyroid resection, whereby a variety of factors such as young age and remnant size, as well as microsomal antibody titers, have shown an inconsistent correlation to postopera¬ tively recurrent GD (1) (2) (3) (4) (5) . Recurrences may be troublesome to manage, especially in patients with histories of endocrine ophthalmopathy (EO), because the immunological activation at recurrency may concomitantly aggravate the eye involvement (6, 7) . Provided that this activation is thyroid-tissue depend¬ ent, the reported variable influences of thyroid resection on EO and therapy-resistant GD (8) (9) (10) (11) (12) (13) may be improved hypothetically by more radical operative procedures.
Thyrotropin receptor antibodies (TSH-R-ab) are generally regarded as mediators of thyroid stimulation in GD (14, 15) . The TSH-R-ab titers characteristically decrease in cases of successful thyrostatic drug treat¬ ment (16, 17) . In addition to goiter size, thyroid hormone levels and age at diagnosis (18) , elevated TSH-R-ab values at the end of medical treatment have been shown to correlate to recurrent GD (19) (20) (21) . The TSH-R-ab titers usually are elevated in patients suffering from EO but fail to correlate to the severity of the eye involvement (22) . Subtotal thyroid resection has been associated with temporary antibody eleva¬ tions, which generally tend to decline during the first postoperative year (5, (23) (24) (25) (26) . The preoperative TSH-R-ab level has not proved to be an accurate predictor of postoperative outcome (25, 27) . Persistently elevated levels after surgery, however, seem to increase the risk of recurrent GD (5, 25) .
The aim of the present study was to examine the outcome of surgery in GD. An analysis of subtotal resection and total thyroidectomy was performed, with particular attention to EO and TSH-R-ab levels.
Patients and methods A retrospective evaluation was performed in 178 consecutive patients with GD who underwent thyroid¬ ectomy at our surgical department during 1980-1992. Preoperatively, 158 of the patients had been treated at our medical department, while the others were admitted from regional hospitals. Five Figure 1 contains the TSH-R-ab data from the "responsive" and "resistant" groups, arranged into two groups, presenting the different cases experiencing remission and recurrent GD following surgery, respectively.
All 15 patients with serial TSH-R-ab titer measure¬ ments subjected to total thyroidectomy received thyro¬ static therapy postoperatively. Eleven of them demon¬ strated completely normalized antibody levels 1-2 years postoperatively and the others showed gradually decreasing levels close to normal 1 year after surgery (Fig. 2) .
Four patients received radioiodine treatment prior to subtotal resection (N = 2) or total thyroidectomy (N = 2). Two of them had EO at the time of diagnosis and the others developed severe EO after radioiodine administration. All of them exhibited high levels of TSH-R-ab preoperatively, which remained largely unaffected by surgery and pre-and postoperative thyrostatic treatment (Fig. 3) .
Patients characterized by persistent or worsening EO and/or highly elevated TSH-R-ab levels in spite of thyrostatic treatment for more that 1 year ("bad responders") were identified. This group contained 75 out of the total 173 cases. Among the individuals undergoing subtotal resection, 23 patients (39%) experienced recurrent GD and 11 (19%) a deterioration in or development of EO, whereas only one patient (6%) subjected to total thyroidectomy developed slightly progressive EO (p < 0.05). In comparison, an analysis of 24 patients subjected to subtotal resection without EO at the time of surgery and with preoperatively normal¬ ized TSH-R-ab levels ("good responders") revealed that 96% stayed in remission and none developed EO during the follow-up. 
